Cholera Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Type, Distribution Channel, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cholera Vaccines Market size was around USD 110.1 million in 2026 and is slated to grow at a 9.5% CAGR from 2027 to 2036, attaining USD 272.85 million by 2036. The industry revenue for 2027 is estimated at USD 118.91 million.
Get more details on this report
Request Free Sample ReportCholera Vaccines Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 39.86% share due to strong procurement systems, advanced public health infrastructure, and coordinated vaccine distribution and preparedness frameworks.
- Asia Pacific grows at 11.31% CAGR due to higher outbreak exposure, expanding immunization campaigns, and increasing preventive vaccination in vulnerable populations.
Segment Momentum
- Killed Oral O1 and O139 held a 63% market share in 2026 due to their suitability for large-scale immunization programs, with oral delivery supporting efficient deployment and broad coverage across target populations.
- Retail pharmacy is growing fastest because it expands community-level vaccine access, offering greater convenience and supporting broader distribution beyond hospital-centered immunization pathways.
Market Expansion Drivers
- Increasing cholera outbreak awareness boosting vaccination programs in endemic regions.
- Expanding global travel and NGO-led immunization campaigns driving vaccine demand.
- WHO elimination targets and technology transfer initiatives expanding vaccine production capacity.
Leading Market Participants
- Major players in the cholera vaccines market include Sanofi S.A. (France), Valneva SE (France), EuBiologics Co., Ltd. (South Korea), Bharat Biotech International Ltd. (India), Serum Institute of India Pvt. Ltd. (India), Emergent BioSolutions Inc. (United States), Incepta Vaccine Ltd. (Bangladesh), Vabiotech (Vietnam), PT Bio Farma (Persero) (Indonesia), Shantha Biotechnics Pvt. Ltd. (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 110.1 million
- 2027 Estimated Market Size: USD 118.91 million.
- Projected Market Size: USD 272.85 million by 2036
- Growth Forecast: 9.5% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Killed Oral O1 and O139 (Type) | Hospital Pharmacy (Distribution Channel) | Dukoral (Product)
- Emerging Opportunity Segment: Killed Oral O1 and O139 (Type) | Retail Pharmacy (Distribution Channel) | Vaxchora (Product)
Market Growth Drivers and Industry Trends
Increasing cholera outbreak awareness boosting vaccination programs in endemic regions
Greater awareness of recurring cholera outbreaks is encouraging public health authorities to strengthen preventive vaccination activities, thereby supporting the cholera vaccines market. Outbreak preparedness has become increasingly important in areas where inadequate sanitation, unsafe water supplies, displacement, and climate-related disruptions can increase exposure to cholera. Awareness of the health and economic consequences associated with outbreaks encourages governments and health organizations to incorporate vaccination into broader prevention and response programs. Targeted immunization campaigns can also help protect vulnerable populations in areas experiencing recurring transmission, particularly when vaccination is combined with improvements in water, sanitation, and hygiene measures.
Expanding global travel and NGO-led immunization campaigns driving vaccine demand
International movement of people and humanitarian activities are increasing the need for coordinated disease-prevention measures, which will drive the cholera vaccines market growth in regions exposed to transmission risks. Travelers, displaced populations, and communities affected by humanitarian emergencies can face elevated exposure where sanitation infrastructure is limited, creating requirements for targeted immunization and outbreak preparedness. Non-governmental organizations and other humanitarian groups play an important role in supporting vaccination campaigns in vulnerable communities, particularly during emergencies and disease-control initiatives. Broader coordination between public health programs and humanitarian organizations is facilitating vaccine deployment where conventional healthcare access may be constrained.
WHO elimination targets and technology transfer initiatives expanding vaccine production capacity
Global disease-control objectives are encouraging investments in vaccine manufacturing capabilities and strengthening the cholera vaccines market. International efforts focused on reducing cholera transmission are increasing attention toward reliable vaccine availability, supply resilience, and production scalability. Technology transfer initiatives can support the development of manufacturing expertise in additional regions, allowing producers to strengthen local or regional vaccine capabilities and reduce dependence on limited production sources. Greater collaboration around manufacturing processes, technical knowledge, and quality requirements is also helping expand the capacity needed to support vaccination programs during routine prevention activities and emergency outbreak responses.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing cholera outbreak awareness boosting vaccination programs in endemic regions | 2.20% | High | Africa, Asia Pacific | High | Near Term |
| Expanding global travel and NGO-led immunization campaigns driving vaccine demand | 1.90% | High | Global | High | Near Term |
| WHO elimination targets and technology transfer initiatives expanding vaccine production capacity | 1.70% | High | Asia Pacific, Africa | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the cholera vaccines market, North America held the largest share at 39.86% in 2026, reflecting advanced healthcare infrastructure, strong public health capabilities, and established access to preventive vaccination services. The region benefits from sophisticated disease surveillance and preparedness systems that support the procurement and deployment of vaccines when infection risks emerge. Greater awareness of infectious disease prevention, combined with well-developed regulatory and healthcare frameworks, also contributes to sustained demand for vaccines targeting cholera and other enteric diseases.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth in the cholera vaccines market, supported by the presence of areas with elevated vulnerability to waterborne diseases, expanding immunization infrastructure, and increasing emphasis on public health preparedness. Improvements in healthcare access and disease surveillance are enabling more effective prevention strategies, while government and public health initiatives are strengthening vaccination coverage in at-risk populations. Growing investment in sanitation, healthcare delivery, and infectious disease control further supports regional demand for cholera vaccines.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Manufacturing FocusGermany supports the cholera vaccines market through advanced pharmaceutical manufacturing standards and investments in vaccine quality and regulatory compliance. German organizations also participate in collaborative research and international health programs that strengthen vaccine availability.
France 🇫🇷
Humanitarian Vaccine SupportFrance maintains a strong focus on cholera vaccines through public health collaborations and participation in international immunization initiatives. French organizations contribute to vaccine research and procurement activities that reinforce access for outbreak response programs.
Italy 🇮🇹
Collaborative Research NetworkItaly advances the cholera vaccines market through academic research, vaccine development partnerships, and public health collaboration. Italian institutions continue supporting projects that improve vaccine production processes and strengthen preparedness for infectious disease management.
Japan 🇯🇵
Public Health PreparednessJapan prioritizes vaccine development technologies and preparedness strategies that strengthen responses to infectious disease risks. Japan also supports cholera vaccine research through partnerships focused on improving formulation quality and supply reliability for international health programs.
South Korea 🇰🇷
Biopharmaceutical ExpansionSouth Korea is strengthening its cholera vaccines market through investments in modern vaccine manufacturing infrastructure and biotechnology capabilities. South Korean companies continue expanding production expertise while supporting regional and global vaccine supply partnerships.
United States 🇺🇸
Global Supply InnovationThe U.S. emphasizes vaccine research, manufacturing capacity, and international procurement partnerships that support cholera immunization programs. U.S.-based organizations continue to prioritize product innovation and scalable production for public health and humanitarian vaccination initiatives.
Segment Leadership and Growth Trends
Cholera Vaccines Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Killed Oral O1 and O139 (Largest & Fastest-Growing Segment)
The killed oral O1 and O139 segment accounted for 63% share of the cholera vaccines market in 2026 and represented both the largest and fastest-growing vaccine type. Its position is supported by the importance of oral vaccination approaches in cholera prevention, particularly in settings where controlling transmission requires practical and scalable immunization strategies. The ability to target the O1 and O139 serogroups, which are associated with cholera disease, strengthens the relevance of this vaccine type in public health programs. Continued emphasis on outbreak preparedness, preventive vaccination, and access to effective cholera control measures supports sustained demand for this segment.
Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)
Hospital pharmacy held the largest share of the cholera vaccines market in 2026 at 48.23%, reflecting the important role of healthcare institutions in vaccine administration, disease prevention, and public health response. Hospital-based distribution provides access to trained healthcare personnel and established vaccination infrastructure, making it particularly relevant for populations requiring organized immunization services. Its role is further supported by the need for coordinated vaccine delivery during disease-control initiatives and in areas facing elevated cholera risks.
Retail pharmacy is the fastest-growing distribution channel as vaccination access increasingly expands beyond traditional hospital settings. Retail-based availability can improve convenience and accessibility for individuals seeking preventive immunization while supporting broader community-level vaccine delivery. The growing emphasis on decentralized healthcare services and easier access to preventive products is creating additional opportunities for pharmacies to participate in vaccine distribution.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Whole Cell V. Cholerae O1 with Recombinant B- Subunit, Killed Oral O1 and O139 | Killed Oral O1 and O139 | Killed Oral O1 and O139 |
| Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Other | Hospital Pharmacy | Retail Pharmacy |
| Product | Vaxchora, Dukoral, Shanchol, Others | Dukoral | Vaxchora |
Competitive Landscape and Market Positioning
Prominent players in the cholera vaccines market:
1. Sanofi S.A. (France)
2. Valneva SE (France)
3. EuBiologics Co. Ltd. (South Korea)
4. Bharat Biotech International Ltd. (India)
5. Serum Institute of India Pvt. Ltd. (India)
6. Emergent BioSolutions Inc. (United States)
7. Incepta Vaccine Ltd. (Bangladesh)
8. Vabiotech (Vietnam)
9. PT Bio Farma (Persero) (Indonesia)
10. Shantha Biotechnics Pvt. Ltd. (India)
The cholera vaccines market is benefiting from increased focus on public health preparedness and vaccine accessibility across high-risk regions. Collaborative research efforts are supporting advancements in vaccine stability, oral delivery systems, and long-term immunity enhancement. Greater emphasis on scalable production and immunization outreach programs is also contributing to stronger market development initiatives.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. (France) | |||||||
| Valneva SE (France) | |||||||
| EuBiologics Co. Ltd. (South Korea) | |||||||
| Bharat Biotech International Ltd. (India) | |||||||
| Serum Institute of India Pvt. Ltd. (India) | |||||||
| Emergent BioSolutions Inc. (United States) | |||||||
| Incepta Vaccine Ltd. (Bangladesh) | |||||||
| Vabiotech (Vietnam) | |||||||
| PT Bio Farma (Persero) (Indonesia) | |||||||
| Shantha Biotechnics Pvt. Ltd. (India). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Biovac Institute | Apr-24 | The Biovac Institute initiated clinical trials for South Africa’s first locally manufactured oral cholera vaccine following regulatory approval. This development marks a material step toward regional vaccine self-sufficiency, reducing reliance on imported supply chains and establishing a new manufacturing footprint to address demand within the African continent. |
| Sapigen Biologix | Apr-24 | Sapigen Biologix announced plans to expand its vaccine manufacturing facility in Odisha, India, with a specific focus on producing oral cholera vaccines. The investment is intended to strengthen India's domestic production capabilities, contributing to global supply resilience and diversifying manufacturing centers for critical immunization products. |
| EuBiologics | Mar-24 | EuBiologics secured WHO prequalification for its second cholera vaccine manufacturing facility in South Korea, a critical milestone for increasing global production capacity. This expansion, combined with the successful development of the Euvichol-S vaccine, is expected to enhance output volumes and optimize cost structures to address persistent global supply shortages. |
| African Union & French Government | Mar-24 | The African Union and the French Government advanced a strategic initiative to foster local vaccine manufacturing across Africa. By focusing on critical vaccines, including cholera, the collaboration aims to structurally reduce dependence on external suppliers, enhance regional manufacturing capacity, and improve long-term supply chain security for the healthcare market. |
| Bavarian Nordic | Feb-23 | Bavarian Nordic acquired the rights to the Vaxchora cholera vaccine from Emergent BioSolutions. The transaction included the transfer of manufacturing facilities in Bern, Switzerland, and San Diego, California, along with associated personnel. This acquisition significantly alters the competitive landscape by consolidating manufacturing assets and intellectual property under Bavarian Nordic’s global vaccine portfolio. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cholera Vaccines Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Age Group | Pediatric, Adolescent, Adult |
| End User | Government & Public Health Agencies, Hospitals & Clinics, Humanitarian Organizations |
| Immunization Program | Routine Immunization Programs, Mass Vaccination Campaigns, Outbreak Response Programs, Travel Vaccination Programs |
Cholera Vaccines Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Global Vaccine Procurement and Tender Intelligence |
|
| Outbreak Preparedness and Stockpile Strategy |
|
| Manufacturing Capacity and Supply Security Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much is the cholera vaccines market worth?
What is the anticipated CAGR of the cholera vaccines industry?
How are preventive immunization strategies reshaping procurement in the cholera vaccines market?
Why are global partnerships and production expansion becoming strategically important in the cholera vaccines market?
Why do Killed Oral O1 and O139 vaccines lead the cholera vaccines market?
Why is retail pharmacy the fastest-growing distribution channel in the cholera vaccines market?
Why does North America lead the cholera vaccines market?
How is Asia Pacific driving fastest growth in cholera vaccines market?
What are the key competitors in the cholera vaccines landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization